CBIO

Crescent Biopharma Stock Analysis

AI Rating

Low
  • Quality3/10
  • Growth↓ 4/10
  • Value↓ 1/10
Crescent Biopharma sales and earnings growth
CBIO Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 78.29%
  • FCF Y/Y↓ -133.13%
Crescent Biopharma gross and profit margin trends
CBIO Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -1419.60%
  • ROIC 5Y↑ 27.90%
Crescent Biopharma net debt vs free cash flow
CBIO Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -68.5

Crescent Biopharma stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗